Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients
Metrics: PDF 793 views | HTML 1614 views | ?
Jiong Hu1,2,3,*, Hai Hu2,3,*, Jun-jie Hang2,3,*, Hai-yan Yang2,3,*, Zhi-yong Wang2,3, Lei Wang2,3, Dong-hui Chen2,3, Li-wei Wang1,2,3
1Department of Medical Oncology, Shanghai General Hospital of Nanjing Medical University, Shanghai 201620, China
2Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China
3Shanghai Key Laboratory of Pancreatic Diseases, Shanghai 201620, China
*These authors contributed equally to this work
Dong-hui Chen, email: email@example.com
Li-wei Wang, email: firstname.lastname@example.org
Keywords: PDAC, PLD1, Sp1, prognosis, immunohistochemistry
Received: March 09, 2016 Accepted: September 20, 2016 Published: October 04, 2016
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with few therapeutic options. Recently, insight into cancer biology suggested abnormal lipid metabolism to be a risk factor for human malignancies. As a key enzyme implicated in lipid metabolism, PLD1 was elevated in various human cancer associating with malignant phenotypes. However, little was known about its expression and function in PDAC. We showed that PLD1 was elevated in both the cell lines and clinical samples of PDAC, and it positively correlated with vascular invasion (p = 0.041) and responsible for a poor prognosis (p = 0.009). Meanwhile, we also found Sp1 to be elevated in the disease, correlating with vascular invasion (p = 0.007). Moreover, the correlation assay suggested that PLD1 positively correlated with Sp1 in the clinical sample (r = 0.390; p < 0.001) and the cell lines. Finally, we showed that co-high expression of both the factors confers the poorest prognosis for the patients, and that their simultaneous high expression might be an independent prognostic factor (p = 0.001; HR = 3.427; 95% CI 1.629−7.211).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.